|
||||||||||||||||||||
|
1019 new pubmed citations were retrieved for your search. These pubmed results were generated on 2011/07/08 PubMed, a service of the National Library of Medicine, includes over 15 million
Metastatic liver tumors. Semin Surg Oncol. 2000 Sep-Oct;19(2):177-88 Authors: McCarter MD, Fong Y The liver is a common site of metastasis from a variety of tumors. In many cases, liver resection for metastatic cancer provides the only chance for a cure and can be performed with less than 5% mortality and acceptable morbidity. The 5-year survival following liver resection for colorectal metastasis is reported in many large series to be 25% to 37%. The data regarding liver resection for other metastatic tumor types are less clear. However, resection for selected tumors, such as neuroendocrine and renal cell, can provide durable palliation and/or cure. We will review important prognostic factors used to guide the selection of patients for resection of metastatic disease and make recommendations for imaging studies and follow-up routines. The role of adjuvant regional and systemic chemotherapy for resectable metastatic disease is also discussed. Methods for ablating unresectable metastatic tumors may prove to be useful adjuncts to current therapies. PMID: 11126381 [PubMed - indexed for MEDLINE]
Transplantation for liver and biliary cancer. Semin Surg Oncol. 2000 Sep-Oct;19(2):189-99 Authors: Strong RW The early survival of patients transplanted for liver and biliary cancer is excellent, but the overall mid- to long-term survival is poor. In an era of severe donor organ shortage, it is not justified to allocate donor liver to patients with a suboptimal outcome. Patients with non-resectable hepatocellular carcinoma in a non-cirrhotic liver should not be assigned to liver transplantation. Although patients with the fibrolamellar variant have a somewhat better outlook, they are still likely to recur, and the young age of many of these patients is likely to overwhelm any rational approach. The results of transplantation for early-stage hepatocellular carcinoma in a cirrhotic liver are similar to those achieved with benign disease. The inclusion of such cases as a group is justified, but attempts should be made to resect tumors whenever possible and to not assign the entire group to transplantation as the first and only option. The value of pre- and postoperative adjuvant therapy for this group is still under debate, but the present waiting period is so long that some form of therapy to slow growth and prevent dissemination of tumor cells is probably required. The results following transplantation for cholangiocarcinoma can only be regarded as dismal, and the diagnosis of cholangiocarcinoma is a contraindication for the procedure. Liver transplantation has a definite place in the treatment of epithelioid hemangioendothelioma and unresectable chemo-responsive hepatoblastoma when confined to the liver, and in a limited number of metastatic neuroendocrine tumors. PMID: 11126382 [PubMed - indexed for MEDLINE]
Recent advances in hepatic resection. Semin Surg Oncol. 2000 Sep-Oct;19(2):200-7 Authors: DeMatteo RP, Fong Y, Jarnagin WR, Blumgart LH Hepatic surgery has emerged over the last three decades and has proven to be a safe and effective treatment for primary and secondary malignancies, as well as for benign diseases of the liver. During the past 10 years, several major advances have been made in 1) surgical technique with the advent of portal pedicle ligation maneuvers and the implementation of mechanical staplers, 2) intraoperative management with the development of low central venous pressure anesthesia, and 3) surgical technology with the innovation of laparoscopy for staging of patients with cancer and performing minimally invasive liver resection. We present a summary of our experience with these advances. PMID: 11126383 [PubMed - indexed for MEDLINE]
Diagnostic imaging approaches and relationship to hepatobiliary cancer staging and therapy. Semin Surg Oncol. 2000 Sep-Oct;19(2):94-115 Authors: Hann LE, Winston CB, Brown KT, Akhurst T Diagnostic imaging plays an essential role in management of hepatobiliary tumors. High resolution images provided by computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound (US) allow detection of tumor within the liver. CT arterial portography remains the standard for detection of small lesions in the range of 1.5 cm, but noninvasive techniques such as contrast-enhanced helical CT and MR hold promise for comparable lesion detection. MRI provides lesion characterization for differentiation of benign and malignant tumors. Lesion characterization has been further improved by faster CT and MR techniques that allow imaging in both arterial and portal venous phases for characterization of lesions based on the rate and pattern of enhancement. Functional imaging such as 2-fluoro-2-deoxy-D-glucose-positron-emission tomography (FDG-PET) is increasingly utilized for detection of intrahepatic tumor and extrahepatic disease. Accuracy of FDG-PET for extrahepatic disease is better than conventional imaging and has been shown to change management in a significant number of patients. Imaging is also invaluable for surgical planning. Segmental anatomy is well shown by CT, MRI, and US. CT or MR angiography with newer 3D techniques delineate vascular variants and areas of encasement or occlusion by tumor. Biliary involvement at the hilus may be shown by US and MR cholangiography. Imaging detection of vascular involvement, bile duct extension, and lobar atrophy may alter the surgical approach. PMID: 11126385 [PubMed - indexed for MEDLINE]
Genes and viruses in hepatobiliary neoplasia. Semin Surg Oncol. 2000 Sep-Oct;19(2):84-93 Authors: Reeves ME, DeMatteo RP Hepatobiliary neoplasms comprise a significant portion of the worldwide cancer burden. Advances in basic science research have led to rapid progress in our understanding of the molecular events responsible for these dreaded diseases. The genetic changes associated with hepatocellular carcinoma (HCC) have received the most attention. Aflatoxin B1 exposure leads to mutations in the p53 tumor suppressor gene, most commonly a transversion in codon 249 that leads to a substitution of serine for arginine in the p53 protein. Numerous other tumor suppressor genes, oncogenes, and tumor gene pathways are altered in HCC. Hepatitis B virus (HBV) infection is strongly associated with HCC. HBV may cause HCC either directly via the HBV X protein, or indirectly by causing liver inflammation and cirrhosis. Hepatitis C virus (HCV) infection is also associated with HCC. Recent evidence suggests that the HCV core protein may play a role in hepatocarcinogenesis. Several inherited metabolic diseases are associated with HCC. It is likely that these diseases cause HCC indirectly by causing cirrhosis. The molecular pathogenesis of cholangiocarcinoma and gallbladder cancer has not been well defined. However, multiple tumor suppressor genes and oncogenes, including p53 and K-ras, are altered in these tumors. Further molecular characterization of hepatobiliary tumors may lead to earlier diagnosis, better staging, improved treatment planning, and the development of more effective therapies. PMID: 11126384 [PubMed - indexed for MEDLINE]
New reconstructive surgery, including microvascular surgery and tissue engineering. Semin Surg Oncol. 2000 Oct-Nov;19(3):209-10 Authors: Robb GL PMID: 11135476 [PubMed - indexed for MEDLINE]
Hepatobiliary cancer. Semin Surg Oncol. 2000 Sep;19(2):83 Authors: Blumgart LH, Fong Y PMID: 11135475 [PubMed - as supplied by publisher]
Mandible reconstruction with microvascular surgery. Semin Surg Oncol. 2000 Oct-Nov;19(3):226-34 Authors: Disa JJ, Cordeiro PG Microvascular surgery has become the preferred method for mandible reconstruction. Whenever possible, immediate reconstruction at the time of segmental mandible resection will provide the best aesthetic and functional result. Four donor sites (fibula, iliac crest, radial forearm, and scapula) have become the primary sources of vascularized bone and soft tissue for the reconstruction. The fibula has multiple advantages, including bone length and thickness, donor site location permitting flap harvest simultaneously with tumor resection, and minimal donor site morbidity. The fibula donor site should be the first choice for most defects, particularly those with anterior or large bony defects requiring multiple osteotomies. Use of an alternative donor site is best reserved for cases with large soft tissue and minimal bone requirements. Dental rehabilitation through the use of prostheses and osseointegrated dental implants is an important part of the reconstructive process to optimize aesthetics and function. An algorithm for mandible reconstruction with microvascular osseous flaps is presented. Semin. Surg. Oncol. 19:226-234, 2000. PMID: 11135479 [PubMed - indexed for MEDLINE]
Challenges in midface reconstruction. Semin Surg Oncol. 2000 Oct-Nov;19(3):218-25 Authors: Cordeiro PG, Disa JJ Defects of the midface and maxilla are often the most challenging problems faced by the reconstructive surgeon. Resections that involve critical structures of the face such as the nose, eyelids, and lips in conjunction with the maxilla can be particularly difficult to reconstruct. The algorithm for reconstruction of these defects is usually based on the extent of maxilla that is resected. A classification system for maxillectomy defects is the most useful way to approach these reconstructions. A vast majority of extensive defects involving the maxilla and midface require free flap reconstructions. The type of flap selected is based on the extent of skin, soft tissue, and bone that is resected. Smaller volume defects with large skin surface requirements are best reconstructed with the radial forearm fasciocutaneous or osteocutaneous flaps. Larger soft-tissue volume and skin surface can be provided by the rectus abdominus myocutaneous flap. Critical structures such as lips, eyelids, and nose should be reconstructed separately, using local flaps if at all possible. The free tissue transfer should ideally not be incorporated into these structures. Most patients with even the largest resections can be restored to fairly good function by following this algorithm. Semin. Surg. Oncol. 19:218-225, 2000. PMID: 11135478 [PubMed - indexed for MEDLINE] |
||||||||||||||||||||
|
|
||||||||||||||||||||
